For more detailed information about the cookies we use, see our Cookies page.
Essential Cookies enable core functionality such as security, network management, and accessibility. These cookies are necessary for the performance of the service and may not be removed.
Non-Essential Cookies are preference, marketing, and functional cookies that help the application perform to its full extent, advertising related to the IdeaScale marketing website, and ensure the application functions properly. Preferences cookies personalize your experience while accessing IdeaScale by remembering your preferences, such as preferred language and region of origin. Analytics cookies collect anonymized information about how you use the IdeaScale services, such as the IdeaScale pages you visit most frequently and the error messages you encounter. These cookies only analyze your movement within IdeaScale and are used to improve the functioning of IdeaScale services. Marketing cookies advertise IdeaScale services to you elsewhere on the Internet. These cookies enable the delivery of interest-based ads that may be relevant to you as a result of your activities on IdeaScale and provide IdeaScale with information (such as where you saw the ad) to help analyze the impact of its advertising campaigns. IdeaScale also includes links to social networks and third-party sites (for example, Facebook and LinkedIn), which may then use information about your visit to target advertising to you on their websites.
Highly active antiretroviral therapy (HAART), while clearly invaluable, does not halt growth or proliferation of HL, in fact, while AIDS-defining malignancies like Kaposi’s sarcoma (KS) and non-Hodgkin’s lymphoma (NHL) have declined thanks to HAART, the incidence of HL in HIV patients has actually increased, from 14 times higher than that of non-HIV patients in the pre-HAART era to 32 times higher in the HAART era. Typical...
Is this idea a Compelling Question (CQ) or Critical Challenge (CC)?
Critical Challenge (CC)
Details on the impact of addressing this CQ or CC
Today, approximately 10% (over 3.5 million worldwide) of HIV-infected patients develop lymphoma. The societal cost of HIV-related HL is particularly steep. HL patients are typically young (20s-30s), likely to actively spread virus, and without treatment, represent years of lost productivity.
Feasibility and challenges of addressing this CQ or CC
To this end, it is important to gather a team of collaborators from the fields of immunology, cancer, immunotherapy, and HIV. Through these combined expertise, we hope to lay the groundwork for novel, life-saving therapy for patients with HL in the problematic context of HIV viral infection.
Name of idea submitter and other team members who worked on this idea